Shilpa Medicare Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Profitability turned the corner: EBITDA jumped 74% YoY to ₹50 crores, pulling consolidated PAT into positive territory, while operating cash flow hit ~₹70 crores.
• The API reset is deliberate, not a warning: CRAMS was stopped by design and a one-time Highseas sale inflated last year's base, so the flat ₹262 crores revenue masks a cleaner, higher-margin core now emerging.
• The pipeline is converting from promise to product: A first US NDA approval (Pemetrexed), a first transdermal patch partnership, an EU Nilotinib filing, and an Adalimumab launch this quarter all signal the R&D engine is starting to pay out.
• The balance sheet is being reshaped, not just deleveraged: A ₹450 crores NCD placement bought a 27-month principal moratorium, while a rights issue remains on the table with deleveraging as its stated purpose.
• What to watch next quarter: Whether the Adalimumab launch lands on schedule, the pace of new product commercialization from Unit 4 and the CMO site, and any update on the US FDA reinspection timeline.

Profitability & Cash Flow Recovery

• EBITDA surge: Consolidated EBITDA reached ₹50 crores, up 74% YoY and 23% sequentially, driven by operational efficiency gains and higher licensing fees from R&D monetization.
• PAT turns positive: The EBITDA improvement was sufficient to swing consolidated PAT into the black for the quarter.
• Operating cash flow: The business generated ~₹70 crores of positive operating cash flow, which management cited as evidence the business is coming back on track.
• Net debt inched lower: Net debt reduced by ~₹19 crores quarter-on-quarter to ₹745 crores, a modest but directionally supportive move ahead of the larger balance-sheet restructuring.
• Licensing fees added ballast: Licensing income this quarter came from a mix of milestone achievements on past agreements and new arrangements, including a transdermal patch deal and an NDA approval milestone; management described licensing fees as a regular feature but stopped short of committing to sustaining the current ₹53 crores level.

Bhutada: "We were losing for, last one or two years because of this unpredictability, not because of us, but on a regulatory front from the US FDA. But now we are coming back on track and we fairly feel that, this will definitely continue, not only continue, it will improve."

The API Reset: What Actually Happened

• CRAMS exit was planned: The CRAMS business has been deliberately brought down and stopped, and no longer appears as a separate segment; this was not a loss of business but a strategic discontinuation.
• One-time base effect: The "others" category in the API business shows volatility because Q1 last year included both the now-discontinued CRAMS business and a one-time Highseas sale of ~₹16 crores related to a slump sale from Shilpa Medicare to Shilpa Pharma.
• Cleaner core underneath: Stripping out those two items, the underlying API performance was steadier than the headline flat revenue suggests, and management expressed confidence that the API business will once again be the crown jewel of performance.
• Facility augmentation complete: The company completed augmentation of facilities to offer peptide, polymer, and CDMO services within the API segment, broadening the addressable market.

Bhutada: "I am confident that our API business once again will be the crown jewel of the performance."

Pipeline Conversion: Products Moving to Market

• First US NDA approved: Pemetrexed injection (1000 mg, 100 mg, 500 mg) received US FDA approval as a ready-to-use product; commercialization is arranged with Amneal Pharmaceutical for the US market, with launch planned under the J-Code program by Q4 FY24.
• Nilotinib capsule filed in Europe: The complex product was filed in Germany via the centralized BCP procedure, partnered with two European customers, and launch is expected in Q2 FY24; pivotal studies for the US are ongoing.
• Adalimumab launch imminent: High-concentration Adalimumab was received for the India market, partnered with Shilpa and one other large Indian company, and launch is expected this quarter.
• Transdermal patch partnership signed: A first partnership deal with a European company was executed; the Ema Science device is already taken, and a pivotal study is planned in Q2-Q3.
• Film formulations enter US market: Vitamin D3, melatonin, methylcobalamin, simethicone, and green tea film formulations were launched into the US as dietary supplements.
• ODF dossier progressed: One ODF product dossier was satisfactorily reviewed by UK MHRA, with approval expected in the near future; Dabaspet Unit 6 received MHRA approval and began commercializing ODF products in the US nutraceutical/dietary supplements category.

Biologics & Novel Assets: Early but Advancing

• NAFLD drug enters Phase 3: SML NUD07 received CDSCO approval and entered Phase 3 clinical study for non-alcoholic fatty liver disease; study completion is expected by Q2 or Q3 FY24.
• Recombinant albumin Phase 1 underway: The study was initiated and NBE (new biological entity) status was received; Phase 1 completion is targeted by December 2023.
• Albumin excipient sales starting: The company expects to begin supplying excipient-grade recombinant albumin this year, with a drug master file being prepared and samples being submitted for formulation approval; current capacity is 1,000 liters per month, and substantial sales are not expected near-term.
• Aflibercept moving to Phase 3: CDSCO approved the Phase 3 study, Phase 1 is already complete, and Phase 3 will start next quarter.
• Biologics CDMO opportunity: Management identified CDMO as the biggest opportunity in biologics and said good leads are coming, though no specifics were quantified.

Regulatory & Manufacturing Milestones

• US FDA inspection cleared: Unit 7 (interim analytical lab) received a VAI classification from the US FDA following a March/April 2023 inspection, marking the second successful US FDA inspection within one year.
• Reinspection awaited: All remediation measures have been completed and the company is waiting for the FDA to schedule a reinspection; the unpredictability on this front was cited as the primary reason for performance losses over the prior one to two years.
• Unit 4 and CMO commercialization progressing: Commercialization of some products into India is ongoing from the Unit 4 site or a CMO site, and commercialization for one more OSD product in the US will start from a CMO site.
• Dabaspet Unit 6 expanding geographically: With MHRA approval in hand, the company plans to soon launch ODF products into Rest of World and European markets.

Balance Sheet & Capital Structure

• NCD placement completed: ₹450 crores of NCDs were issued to select marquee investors on a private placement basis, carrying an initial moratorium period of 27 months; management framed this as a debt portfolio reorganization to spread repayment obligations in line with expected future cash inflows and ease pressure on cash flow.
• Interest rate undisclosed: When asked to quantify the NCD interest rate, management declined to provide an immediate figure, saying it would be shared in due course.
• Rights issue still planned: A rights issue remains on the table with the predominant intent of deleveraging the balance sheet; the apparent contradiction between a prior stance of strictly not wanting to add more debt and the NCD issuance was addressed by management as reorganization rather than adding debt burden, though the tension was not fully resolved.
• Albumin investment undisclosed: When asked for the total investment in the albumin business (capex plus development), management deferred, saying it would come back to the question.

Guidance & Commitments

Key Metrics